{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-047493","form_type":"8-K","ticker":"SCNI","cik":"0001611747","company_name":"Scinai Immunotherapeutics Ltd.","filed_at":"2023-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.664860+00:00","generated_at":"2026-06-14T04:59:15.616391+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BiondVax enters exclusive worldwide license for IL-17 NanoAbs from Max Planck and UMG","bullets":["Exclusive worldwide license to develop and commercialize VHH antibodies (NanoAbs) targeting IL-17 for all indications.","Within 45 days of June 4, 2023, BiondVax will issue 17,000 American Depositary Shares to licensors, with a 1-year lock-up.","Milestone payments due upon IND submission and clinical study initiations; royalties on net sales apply.","BiondVax must submit an IND by June 30, 2025, or face termination by December 31, 2026, unless extended via EUR 500,000 payments.","Plans to initiate a preclinical in vivo efficacy study in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-047493","json":"https://secwatch.observer/filing/0001213900-23-047493.json","markdown":"https://secwatch.observer/filing/0001213900-23-047493.md","text":"https://secwatch.observer/filing/0001213900-23-047493.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1611747/000121390023047493/0001213900-23-047493-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1611747/000121390023047493/ea180017-8k_biondvax.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T04:59:15.616391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12d37fb68764be19629bc8b33fe8cb9fe26beb31","claim":"Scinai Immunotherapeutics Ltd. entered into License Agreement with Max-Planck-Innovation GmbH and the University Medical Center Gottingen (effective 2023-06-04).","evidence_excerpt":"On June 4, 2023, BiondVax Pharmaceuticals Ltd. (the “Company” or “BiondVax”) entered into a License Agreement (the “License Agreement”) with the Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany(“MI”) and the University Medical Center Gottingen (“UMG”) to develop and commercialize VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) (the “Target”) as treatments for all potential indications.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1611747/000121390023047493/0001213900-23-047493-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Max-Planck-Innovation GmbH and the University Medical Center Gottingen"},{"label":"Effective","value":"2023-06-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}